Cationic Steroidal Antimicrobial Compounds for Coronavirus Deactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for addressing coronavirus infections, particularly COVID-19, lack effective and safe compositions and methods for deactivating coronaviruses, with existing vaccines being experimental and innate immunity insufficient in preventing severe infections.
Innovation Solution
Administration of cationic steroidal antimicrobial (CSA) compounds in various carriers, such as water or alcohol, via topical, inhalation, or parenteral routes, to deactivate coronavirus virions, either on surfaces or within subjects, thereby preventing or reducing the severity of infections like COVID-19.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are developed and administered to prevent coronavirus infection, then immunity protection is improved, but safety and efficacy are uncertain due to experimental status
Solution Approach 1:
The patent uses cationic steroidal antimicrobial compounds as an intermediary substance that bridges the gap between innate immunity enhancement and adaptive immunity development. These compounds directly deactivate coronaviruses while stimulating innate immune responses, providing protection without requiring experimental vaccines.
2Reliability
If herd immunity is achieved through broad population exposure, then virus transmission is stopped, but morbidity cost increases significantly
Solution Approach 1:
The patent applies preliminary action by administering cationic steroidal antimicrobial compounds before coronavirus infection occurs. This preventive approach deactivates viruses upon contact and primes innate immunity, eliminating the need for broad population exposure and associated morbidity costs.
3Duration of action of stationary object
If innate immunity is relied upon to protect against coronavirus, then continuous protection is provided, but protection is insufficient against severe infections
Solution Approach 1:
The patent changes the functional parameters of innate immunity by introducing cationic steroidal antimicrobial compounds that enhance its capabilities. These compounds amplify innate immune responses and add direct viral deactivation function, transforming insufficient protection into robust defense against severe coronavirus infections.
Data Source
AI summary
The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition to a subject, and the deactivation composition deactivating coronavirus virions in the subject or coming into contact with the subject. The method can thereby prevent, decrease, or inhibit a coronavirus infection, such as COVID-19, of the subject.